Open AccessDiffuse large B cell lymphoma coexistence with systemic mastocytosis
Author(s) -
Sheng-Hsuan Chien,
YaoChung Liu,
Ying-Chung Hong,
ChingFen Yang,
Chunyu Liu,
TzeonJye Chiou,
ChengHwai Tzeng,
Jin-Hwang Liu,
JyhPyng Gau
Publication year - 2016
Publication title -
journal of cancer research and practice
Language(s) - English
Resource type - Journals
eISSN - 2589-0425
pISSN - 2311-3006
DOI - 10.1016/j.jcrpr.2015.09.001
Subject(s) - systemic mastocytosis , medicine , mast cell , bone marrow , lymphoma , disease , myeloid , neoplasm , immunology , pathology
Systemic mastocytosis is a rare disease and characterized by excessive mast cell accumulation in one or multiple organs. One subtype of systemic mastocytosis is systemic mastocytosis-associated clonal hematological non-mast cell lineage disease (SM-AHMND), which indicates concurrent evolution of two separate clonal entities, one consisting of mast cells and one as a second hematological as well as non-mast cell origin disease. When SM-AHMND is diagnosed, bone marrow examination is essential for the initial approach, because marrow is almost universally involved in adult mastocytosis and it facilitates detection of a second hematological neoplasm. Myeloid neoplasm is reported to be the most prevalent associated clonal hematological non-mast cell disease. Treatment strategy and outcome for SM-AHMND is dependent on hematological non-mast cell lineage disease. Herein, we have presented a case report of diffuse large B cell lymphoma coexisting with systemic mastocytosis where the patient underwent successful chemotherapy leading to extended survival duration